ArticleScientific reports2021
Network pharmacology and molecular docking study on the active ingredients of qidengmingmu capsule for the treatment of diabetic retinopathy.
Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 37 citations in OpenAlex.
- Qideng Mingmu Capsules Ameliorates Retinal Neovascularization by Regulating Ang/Tie2 Signaling Pathway.Chinese journal of integrative medicine · 2026Article
- Non-invasive pharmacological advances in early retinopathy treatment: bioactive herbal compounds, polymer delivery systems, and computational bioprospecting of functional targets.Pharmacological reports : PR · 2026Review
- Network Pharmacology Integrated Molecular Docking Analysis Identifies Potential Phytochemicals in Stachys lavandulifolia against Polycystic Ovary Syndrome.Current pharmaceutical design · 2026Article
- Integrative network pharmacology and molecular modeling approaches reveal the therapeutic potential ofFrontiers in bioinformatics · 2026Article
- Baicalein Reduces Pyroptosis of Acinar Cells in Hyperlipidemic Acute Pancreatitis by Inhibiting M1 Polarization of Macrophages via the HMGB1/TLR4/NLRP3 Pathway.Inflammation · 2025Article
- Integrative systems biology and in-vitro analysis of cryptolepine's therapeutic role in breast cancer.Discover oncology · 2025Article
- Molecular docking and network pharmacology study on active compounds ofIn silico pharmacology · 2024Article
- Hua-Feng-Dan Alleviates LPS-induced Neuroinflammation by Inhibiting the TLR4/Myd88/NF-κB Pathway: Integrating Network Pharmacology and Experimental Validation.Current pharmaceutical design · 2024Article
- Decoding the molecular mechanism of stypoldione against breast cancer through network pharmacology and experimental validation.Saudi journal of biological sciences · 2023Article
- Mechanistic elucidation of Juglanthraquinone C targeting breast Cancer: A network Pharmacology-based investigation.Saudi journal of biological sciences · 2023Article
- Deciphering the mechanisms of Yinlan Tiaozhi capsule in treating hyperlipidemia by combining network pharmacology, molecular docking and experimental verification.Scientific reports · 2023Article
- The Abundant Phytocannabinoids in Rheumatoid Arthritis: Therapeutic Targets and Molecular Processes Identified Using Integrated Bioinformatics and Network Pharmacology.Life (Basel, Switzerland) · 2023Article
- Network Pharmacology and Molecular Docking Study on the Multi-Target Mechanisms ofPlants (Basel, Switzerland) · 2022Article
- Network Pharmacology and Molecular Docking Elucidate the Underlying Pharmacological Mechanisms of the HerbViruses · 2022Article
- [Anti-tumor mechanism of sesquiterpenoids fromNan fang yi ke da xue xue bao = Journal of Southern Medical University · 2022Article
- Celastrol Alleviates Autoimmune Hepatitis Through the PI3K/AKT Signaling Pathway Based on Network Pharmacology and Experiments.Frontiers in pharmacology · 2022Article
- Molecular Mechanism of Food-Derived Polyphenols on PD-L1 Dimerization: A Molecular Dynamics Simulation Study.International journal of molecular sciences · 2021Article
Corrections and comments
- Erratum issued
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic retinopathy (DR) is a leading cause of irreversible blindness globally. Qidengmingmu Capsule (QC) is a Chinese patent medicine used to treat DR, but the molecular mechanism of the treatment remains unknown. In this study, we identified and validated potential molecular mechanisms involved in the treatment of DR with QC via network pharmacology and molecular docking methods. The results of Ingredient-DR Target Network showed that 134 common targets and 20 active ingredients of QC were involved. According to the results of enrichment analysis, 2307 biological processes and 40 pathways were related to the treatment effects. Most of these processes and pathways were important for cell survival and were associated with many key factors in DR, such as vascular endothelial growth factor-A (VEGFA), hypoxia-inducible factor-1A (HIF-1Α), and tumor necrosis factor-α (TNFα). Based on the results of the PPI network and KEGG enrichment analyses, we selected AKT1, HIF-1α, VEGFA, TNFα and their corresponding active ingredients for molecular docking. According to the molecular docking results, several key targets of DR (including AKT1, HIF-1α, VEGFA, and TNFα) can form stable bonds with the corresponding active ingredients of QC. In conclusion, through network pharmacology methods, we found that potential biological mechanisms involved in the alleviation of DR by QC are related to multiple biological processes and signaling pathways. The molecular docking results also provide us with sound directions for further experiments.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.